

CREATING A HEALTHIER WORLD

Liver disease is one of the leading causes of illness and death worldwide.¹

Low awareness of liver diseases in Asia remains a key challenge towards realizing the World Health Organization's (WHO) goal to eliminate viral hepatitis as a public health threat by 2030.

Gilead, together with local communities and partners, are committed to enabling people living with hepatitis to lead long and fulfilling lives.



1M

deaths due to complications of liver cirrhosis and **1M** due to viral hepatitis and hepatocellular carcinoma² annually



354M

people living with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections globally³



90%

90% of people living with HBV⁴ and 79% living with HCV are unaware of their status⁵



Viral hepatitis is the primary cause of liver cancer, causing **69%** of global liver cancer deaths^{6,7}



Asia accounted for

80%

of global hepatocellular carcinoma cases⁸



Asia accounted for

54%

of global cirrhosis-related mortality⁹

¹ Sarin, S. K., Malwall, R. (n.d.). Global Burden Of Liver Disease: A True Burden on Health Sciences and Economies. World Gastroenterology Organization. www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/global-burden-of-liver-disease-a-true-burden-on-health-sciences-and-economies ² Asrani, S. K., Devarbhavi, H., Eaton, J., Kamath, P. S. (2018). Burden of Liver Diseases in the World. *Journal of Hepatology*, 70(1), 151-171. doi.org/10.1016/j.jhep.2018.09.014 ³ World Health Organization (2021, July 28). World Hepatitis Day 2021. www.who.int/news/item/28-07-2021/hepatitis-can-i-wait—who-commemorates-world-hepatitis-day-2021 ⁴ World Health Organization (2021, July 27). Fact sheets: Hepatitis B. www.who.int/news-room/fact-sheets/detail/hepatitis-b ⁵ World Health Organization (2021, July 27). Fact sheets: Hepatitis C. www.who.int/news-room/fact-sheets/detail/hepatitis-c ⁶ Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. (2020). The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level: Results from the Global Burden of Disease Study 2017. *Liver Cancer*, 9(5), 563-582. <https://doi.org/10.1159/000508568> ⁷ The Coalition for Global Hepatitis Elimination (2020, July 28). Interim Report: Progress towards Global Hepatitis Elimination. www.globalhep.org/news/blog-key-takeaways-interim-report-card-progress-towards-global-hepatitis-elimination ⁸ Gandhi M., Ling W. H., Chen C. H., et al. (2021). Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study. *Journal of Hepatocellular Carcinoma*, 2021(6), 1159-1167. doi.org/10.2147/JHC.S329018 ⁹ Sarin, S. K., et al. (2020). Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. *Lancet Gastroenterol Hepatol* 5(2), 167-228. doi:10.1016/S2468-1253(19)30342-5



Fostering collaboration in research and development

- Over the past five years, Gilead has supported more than 140 clinical trials, investigator-sponsored researches and collaborative studies in Asia Pacific in the areas of HBV, HCV, HDV and NASH.
- Gilead is committed to advancing therapies for NASH. In 2019, Gilead partnered with Yuhan Corporation to co-develop novel treatments for patients with advanced fibrosis due to NASH.



Centering efforts around patients and the community

Gilead Asia Pacific Liver Index Study¹¹

- The [Gilead Asia Pacific Liver Index Study](#) measured public knowledge of liver health in 11 markets in the region and revealed gaps on disease transmission, progression as well as apathy to screen and seek treatment.
- A collaborative multi-sectoral approach is called upon to close the identified gaps.

Elevating Voices of People living with HBV

- The inspiring [film series](#) produced by BBC storyworks, is created in partnership with [Coalition to Eradicate Viral Hepatitis in Asia Pacific](#) (CEVHAP) and [World Hepatitis Alliance](#) (WHA).
- The series brings discussions of hepatitis to the forefront and empower those living with, or vulnerable to HBV, to step up their own care.

OUR COMMITMENT TO CREATING A HEALTHIER WORLD THAT IS HEPATITIS FREE

At Gilead Sciences, we have been at the forefront of advancing the care of people living with liver disease, including viral hepatitis. We are committed to realizing the World Health Organization's (WHO) 2030 goal to eliminate viral hepatitis as a public health threat by advancing science and access to treatment.



Advancing science in HBV, HCV and HDV treatment

- At the forefront of innovative treatment, Gilead has introduced four curative treatments for chronic HCV in less than four years.
- In 2016, Gilead launched a new therapy for people living with chronic HBV infection — the first medication for HBV approved by FDA in nearly a decade.¹⁰ Our scientists continue to actively pursue multiple pathways toward a possible cure.

¹⁰ U.S. FDA approved Vemlidy® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic HBV infection and compensated liver disease on 10 November 2016.
¹¹ Lee M.H., et al. (2022). Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large-scale Asian study. *Journal of Viral Hepatitis*, 29(2), 156-170. doi: 10.1111/jvh.1363



Liver